![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JP Hieble, RM DeMarinis, PJ Fowler and WD Matthews
SK&F 86466 (6-chloro-N-methyl-2,3,4,5-tetrahydro-1-H-3-benzazepine) is a potent and selective antagonist at alpha-2 adrenoceptors. Prejunctional alpha-2 adrenoceptor antagonism can be demonstrated either by blockade of the alpha-2 adrenoceptor-mediated neuroinhibitory effect of clonidine or B-HT 920 in the guinea-pig atrium [receptor dissociation constant (KB) = 13-17 nM] or by potentiation of nerve- evoked release of [3H]norepinephrine from prelabeled guinea-pig atria, dog splenic artery or rabbit ear artery. Blockade of the postjunctional alpha-2 adrenoceptor was also seen, as demonstrated by a parallel shift to the right of the concentration-response curve for B-HT 920 as a constrictor agent in the dog saphenous vein. The KB for SK&F 86466 in this test system was 42 nM. The affinity of SK&F 86466 for the alpha-1 adrenoceptor is much lower, with a KB of 900 nM against norepinephrine- mediated constriction in the rabbit ear artery, or 1100 nM vs. SK&F 89748-induced constriction in the dog saphenous vein. The alpha-2/alpha- 1 adrenoceptor selectivity ratio of SK&F 86466 is comparable to that obtained with agents such as yohimbine, making SK&F 86466 a useful tool for characterization of alpha-2 adrenoceptors and for investigation of their physiological role.
This article has been cited by other articles:
|
|
 |
|
  L. S. Stone, K. F. Kitto, J. C. Eisenach, C. A. Fairbanks, and G. L. Wilcox ST91 [2-(2,6-Diethylphenylamino)-2-imidazoline Hydrochloride]-Mediated Spinal Antinociception and Synergy with Opioids Persists in the Absence of Functional {alpha}-2A- or {alpha}-2C-Adrenergic Receptors J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanabe, Y. Kino, M. Honda, and H. Ono Presynaptic I1-Imidazoline Receptors Reduce GABAergic Synaptic Transmission in Striatal Medium Spiny Neurons J. Neurosci., February 8, 2006; 26(6): 1795 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ferreira Jr, N. Sahibzada, M. Shi, W. Panico, M. Niedringhaus, A. Wasserman, K. J. Kellar, J. Verbalis, and R. A. Gillis CNS Site of Action and Brainstem Circuitry Responsible for the Intravenous Effects of Nicotine on Gastric Tone J. Neurosci., April 1, 2002; 22(7): 2764 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Fairbanks, L. S. Stone, K. F. Kitto, H. O. Nguyen, I. J. Posthumus, and G. L. Wilcox alpha 2C-Adrenergic Receptors Mediate Spinal Analgesia and Adrenergic-Opioid Synergy J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hayar and P. G. Guyenet Prototypical Imidazoline-1 Receptor Ligand Moxonidine Activates Alpha2-Adrenoceptors in Bulbospinal Neurons of the RVL J Neurophysiol, February 1, 2000; 83(2): 766 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Fairbanks and G. L. Wilcox Moxonidine, a Selective alpha 2-Adrenergic and Imidazoline Receptor Agonist, Produces Spinal Antinociception in Mice J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 403 - 412. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. G. Guyenet Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites? Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1997; 273(5): R1580 - R1584. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
